The adjuvant endocrine treatment revolution: focus on anastrozole.

about

Malignancy-associated dyslipidemia.

P2860

Q35030677-06A1722E-D721-4AE6-86A1-74736AB6D2A2

P2860

The adjuvant endocrine treatment revolution: focus on anastrozole.

Item

http://www.wikidata.org/entity/Q36546281

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

The adjuvant endocrine treatment revolution: focus on anastrozole.

@ast

The adjuvant endocrine treatment revolution: focus on anastrozole.

@en

type

Item

label

The adjuvant endocrine treatment revolution: focus on anastrozole.

@ast

The adjuvant endocrine treatment revolution: focus on anastrozole.

@en

prefLabel

The adjuvant endocrine treatment revolution: focus on anastrozole.

@ast

The adjuvant endocrine treatment revolution: focus on anastrozole.

@en

P1476

The adjuvant endocrine treatment revolution: focus on anastrozole.

@en

P2093

Raimund Jakesz

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Cancer statistics, 2005

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

P304

301-312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2.2.301

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16866615

http://www.w3.org/2001/XMLSchema#string

The adjuvant endocrine treatment revolution: focus on anastrozole.

about

P2860

P2860

The adjuvant endocrine treatment revolution: focus on anastrozole.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698